Nebula Research & Development LLC Makes New $354,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Nebula Research & Development LLC acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,027 shares of the biopharmaceutical company's stock, valued at approximately $354,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Celldex Therapeutics by 23.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after purchasing an additional 676,771 shares during the period. Silverarc Capital Management LLC increased its holdings in Celldex Therapeutics by 82.5% in the 4th quarter. Silverarc Capital Management LLC now owns 264,560 shares of the biopharmaceutical company's stock valued at $6,685,000 after purchasing an additional 119,560 shares in the last quarter. Eversept Partners LP lifted its position in Celldex Therapeutics by 27.4% during the 4th quarter. Eversept Partners LP now owns 719,836 shares of the biopharmaceutical company's stock worth $18,190,000 after acquiring an additional 154,934 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Celldex Therapeutics during the fourth quarter worth $233,000. Finally, Rock Springs Capital Management LP grew its stake in shares of Celldex Therapeutics by 10.7% during the fourth quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company's stock valued at $30,885,000 after acquiring an additional 118,404 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on CLDX. The Goldman Sachs Group decreased their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Morgan Stanley started coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 target price for the company. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Tuesday. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Stock Performance

NASDAQ CLDX traded down $1.16 on Tuesday, reaching $19.13. The company had a trading volume of 85,907 shares, compared to its average volume of 881,433. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -7.46 and a beta of 1.39. The company's fifty day moving average is $19.09 and its 200-day moving average is $23.07. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.